Free Trial
NYSEARCA:BBP

Virtus LifeSci Biotech Products ETF (BBP) Price, Holdings, & News

$60.26 +0.34 (+0.57%)
(As of 12/20/2024 04:32 PM ET)

About Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP)

Key Stats

Today's Range
$60.10
$60.81
50-Day Range
$59.76
$68.45
52-Week Range
$50.43
$69.12
Volume
1,400 shs
Average Volume
1,928 shs
Market Capitalization
$21.09 million
Assets Under Management
$20.96 million
Dividend Yield
0.00%
Net Expense Ratio
0.79%
Aggregate Rating
Moderate Buy

ETF Overview

The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus.

Virtus LifeSci Biotech Products ETF Expenses

TypeBBPHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.79%0.57%0.55%0.51%0.52%
Other Expenses0.00%0.30%0.49%0.57%0.53%
Total Expense0.79%0.70%0.71%0.73%0.71%
Fee Waiver0.00%-0.45%-0.51%-0.67%-0.56%
Net Expense0.79%0.61%0.61%0.58%0.59%
Receive BBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Products ETF and its competitors with MarketBeat's FREE daily newsletter.

BBP ETF News Headlines

Canadian ETF Comparison Series: FCUQ vs. ZUQ.F
BBP Virtus LifeSci Biotech Products ETF
This Indicator called BOTH NVDA rallies
Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…
Virtus LifeSci Biotech Products ETF (BBP)
Virtus LifeSci Biotech Clinical Trials ETF (BBC)
Spinnaker ETF Series (OOSP)
See More Headlines

BBP ETF - Frequently Asked Questions

Virtus LifeSci Biotech Products ETF's stock was trading at $58.09 on January 1st, 2024. Since then, BBP stock has increased by 3.7% and is now trading at $60.26.
View the best growth stocks for 2024 here
.

Virtus LifeSci Biotech Products ETF's top institutional shareholders include Jag Capital Management LLC (1.15%).

Shares of BBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Products ETF investors own include Inovio Pharmaceuticals (INO), Micron Technology (MU), Sanofi (SNY), Gilead Sciences (GILD), Simon Property Group (SPG), Intel (INTC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

Fund Details

Issuer
Virtus
Fund Name
Virtus LifeSci Biotech Products ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:BBP
Inception Date
12/16/2014
Fund Manager
Matthew B. Brown, Seth Kadushin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
LifeSci Biotechnology Products Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
67

Fund Statistics

Assets Under Management
$20.96 million
Average Daily Volume
$1,510.10
Discount/Premium
-0.12%

Administrator, Advisor and Custodian

Administrator
Virtus ETF Solutions, LLC
Advisor
Virtus ETF Advisers LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
ETF Distributors LLC
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
1,200 shs

Miscellaneous

Beta
0.89
Creation Unit
50,000
Creation Fee
$500.00
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Top 10 BBP Holdings

BBP Sector Exposure

BBP Industry Exposure


This page (NYSEARCA:BBP) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners